Tuberculosis kills more people than any other infectious disease, and approximately one-third of the world's population is latently infected with Mycobacterium tuberculosis. This situation is largely due to the low efficacy of the only licensed TB vaccine, BCG, and the 'black box' of what constitutes protection against TB. This project aims to unravel the mechanisms of protective immunity against TB to develop a highly protective vaccine.